Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pemvidutide - Altimmune

Drug Profile

Pemvidutide - Altimmune

Alternative Names: ALT-801- Altimmune; SP-1373; VPD-107

Latest Information Update: 11 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Velocity Pharmaceutical Development
  • Developer Altimmune; Velocity Pharmaceutical Development
  • Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies; Peptides
  • Mechanism of Action Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis; Obesity
  • Phase I Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
  • Preclinical Dyslipidaemias; Hepatic fibrosis

Most Recent Events

  • 05 Jun 2024 Updated efficacy data from a phase Ib trial in Non-alcoholic fatty liver disease released by Altimmune
  • 09 May 2024 Altimmune expects the End-of-Phase II meeting with the US FDA, regarding the phase III pemvidutide obesity registrational program, in the late third quarter
  • 29 Mar 2024 Preclinical trials in Dyslipidaemias in USA (unspecified route)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top